MK-4827, also known as niraparib, is a novel 2-phenyl-2H-indazole-7-carboxamide PARP inhibitor that displayed anti-proliferation activities against BRCA1- and BRCA2-deficient cancer cells in vitro. Here, BRCA2 is linked to cancer.